.svg){kind=small}
Where to Buy
Quality Drugs is stocked at 70 licensed dispensaries across Oregon, with the deepest coverage in Portland, Eugene, Medford, Ontario, and Beaverton. Search by ZIP code or city below to find the closest one, or filter by product type if you are after a specific format.
Market Insights Snapshot
Quality Drugs concentrated entirely in Edible during August 2026, with category share at 100.0% and a month-over-month change of 6.84% alongside a year-over-year change of 50.42%. The brand’s average price fell 20.25% YoY while maintaining a 6.84% MoM sales lift, and its Edible position sat at rank 9 in Oregon. The pattern implies a price-led volume expansion that is fully anchored in Edible, where a sub-$6 average ticket is supporting faster unit throughput without category diversification.
With a 50.42% YoY gain in an all-Edible mix and a 20.25% YoY price decline, Quality Drugs is trading margin for rank stability at position 9 in Oregon while capturing incremental MoM momentum of 6.84%. The combination of a 100.0% Edible mix and a 6.84% MoM trajectory suggests the brand’s current positioning is volume-centric, implying headroom to climb from rank 9 by sustaining price efficiency while selectively testing premium tiers that do not reverse the YoY unit elasticity.
Competitive Landscape
Quality Drugs sits at rank #9 in OR Edible for August 2026, improving 3 positions year over year from #12 and edging up 1 place since May 2026 when it was #10; however, it remains 1 spot below its peak of #8 from April 2025, indicating partial recovery but not a new high. Against incumbents, Wyld held at #1 year over year while posting a -1.5% YoY sales change, and Mule Extracts maintained #5 with a +2.8% YoY sales change, positioning Quality Drugs closer to mid-tier movers than to the top-two where Gron / Grön stayed at #2 with a -5.8% YoY shift. The combination of a 3-rank YoY climb and only a 1-rank gain over the last three months implies Quality Drugs is advancing primarily on longer-cycle momentum rather than near-term acceleration.
Notable Products
Assorted Caramels 10-Pack (100mg) posted the steepest shift in August 2026, down 24.5% MoM to rank 9 while THC/CBD 2:1 Radiant Raspberry Gummy (100mg THC, 50mg CBD) fell 13.6% at rank 2, implying demand is tilting away from legacy confections toward fruit-forward SKUs. By contrast, Super Sour Apple Gummy (100mg) jumped 45.7% MoM at rank 5 and Watermelon Gummy (100mg) rose 28.7% at rank 3, with Cosmic Pop Gummy (100mg) up 17.9% holding rank 1, signaling momentum in tart and classic fruit profiles. Eight of the top ten are Edible gummies, and the two 1:1:1 gumdrops at ranks 7–8 grew 8.1% and 10.1% respectively, consolidating the portfolio’s center of gravity in balanced or fruit SKUs with fewer gains for caramel formats. The mix points to Quality Drugs concentrating commercial bets on gummy innovation and multi-cannabinoid blends while deprioritizing slower-moving caramel-based items.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
